EDGAR Filing Documents for 0001493152-24-026477

Form 8-K - Current report:

SEC Accession No. 0001493152-24-026477

Filing Date

2024-07-08

Accepted

2024-07-08 16:30:15

Documents

Period of Report

2024-07-01

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1		form8-k.htm iXBRL	8-K	47528
2		ex10-1.htm	EX-10.1	7146
3		ex10-2.htm	EX-10.2	2476
4		ex10-1_001.jpg	GRAPHIC	333317
5		ex10-1_002.jpg	GRAPHIC	507613
6		ex10-1_003.jpg	GRAPHIC	269468
7		ex10-1_004.jpg	GRAPHIC	82406
8		ex10-1_005.jpg	GRAPHIC	284433
9		ex10-1_006.jpg	GRAPHIC	457884
10		ex10-1_007.jpg	GRAPHIC	134172
11		ex10-2_001.jpg	GRAPHIC	282769
12		ex10-2_002.jpg	GRAPHIC	457923
13		ex10-2_003.jpg	GRAPHIC	134172
	Complete submission text file	0001493152-24-026477.txt		4335784

Data Files

Seq	Description	Document	Type	Size
14	XBRL SCHEMA FILE	cldi-20240701.xsd	EX-101.SCH	3813
15	XBRL DEFINITION FILE	cldi-20240701_def.xml	EX-101.DEF	26683
16	XBRL LABEL FILE	cldi-20240701_lab.xml	EX-101.LAB	36817
17	XBRL PRESENTATION FILE	cldi-20240701_pre.xml	EX-101.PRE	25307
28	EXTRACTED XBRL INSTANCE DOCUMENT	form8-k_htm.xml	XML	5962

Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121

Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600

Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)